<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mediators Inflamm</journal-id><journal-id journal-id-type="publisher-id">MI</journal-id><journal-title>Mediators of Inflammation</journal-title><issn pub-type="ppub">0962-9351</issn><issn pub-type="epub">1466-1861</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1155/2007/32403</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Study</subject></subj-group></article-categories><title-group><article-title>The Levels of Ghrelin, TNF-<inline-formula><mml:math id="M1"><mml:mrow><mml:mi>&#x003b1;</mml:mi></mml:mrow></mml:math></inline-formula>, and IL-6 in Children with Cyanotic and Acyanotic Congenital Heart Disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yilmaz</surname><given-names>Erdal</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Ustundag</surname><given-names>Bilal</given-names></name><xref ref-type="aff" rid="I2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sen</surname><given-names>Yasar</given-names></name><xref ref-type="aff" rid="I3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Akarsu</surname><given-names>Saadet</given-names></name><xref ref-type="aff" rid="I4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Nese citak Kurt</surname><given-names>A.</given-names></name><xref ref-type="aff" rid="I4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Dogan</surname><given-names>Yasar</given-names></name><xref ref-type="aff" rid="I4"><sup>4</sup></xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Division of Pediatric Cardiology, Department of Pediatrics, School of Medicine, Firat University, Elaz&#x00131;&#x0011f; 23119, Turkey</aff><aff id="I2"><sup>2</sup>Department of Biochemistry, School of Medicine, Firat University, Elaz&#x00131;&#x0011f; 23119, Turkey</aff><aff id="I3"><sup>3</sup>Division of Pediatric Endocrinology, Department of Pediatrics, School of Medicine, Firat University, Elaz&#x00131;&#x0011f; 23119, Turkey</aff><aff id="I4"><sup>4</sup>Department of Pediatrics, School of Medicine, Firat University, Elaz&#x00131;&#x0011f; 23119, Turkey</aff><author-notes><corresp id="cor1">*Erdal Yilmaz: <email>erdalyilmaz@firat.edu.tr</email></corresp></author-notes><pub-date pub-type="ppub"><year>2007</year></pub-date><pub-date pub-type="epub"><day>4</day><month>9</month><year>2007</year></pub-date><volume>2007</volume><elocation-id>32403</elocation-id><history><date date-type="received"><day>16</day><month>3</month><year>2007</year></date><date date-type="accepted"><day>6</day><month>7</month><year>2007</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2007 Erdal Yilmaz et al.</copyright-statement><copyright-year>2007</copyright-year><license license-type="open-access"><p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><p><italic>Background/Aim</italic>. Ghrelin has effects on nutrient intake and growth. The cause of growth retardation in congenital heart disease is multifactorial. The aim of the present study is to investigate the ghrelin in congenital heart disease and the association of ghrelin with TNF-<inline-formula><mml:math id="M2"><mml:mrow><mml:mi>&#x003b1;</mml:mi></mml:mrow></mml:math></inline-formula> and IL-6. <italic>Materials and methods</italic>. We measured serum ghrelin, TNF-<inline-formula><mml:math id="M3"><mml:mrow><mml:mi>&#x003b1;</mml:mi></mml:mrow></mml:math></inline-formula>, and IL-6 levels using spesific immunoassay in 68 patients (47 acyanotic, 21 cyanotic with congenital heart disease) and in 25 control subjects. <italic>Results</italic>. In comparison to controls, serum ghrelin, TNF-<inline-formula><mml:math id="M4"><mml:mrow><mml:mi>&#x003b1;</mml:mi></mml:mrow></mml:math></inline-formula> levels were significantly higher in acyanotic patients and cyanotic patients with congenital heart disease (<inline-formula><mml:math id="M5"><mml:mrow><mml:mi>P</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>.0001</mml:mn></mml:mrow></mml:math></inline-formula>). In acyanotic and cyanotic patients with congenital heart disease, there was a positive correlation between ghrelin and TNF-<inline-formula><mml:math id="M6"><mml:mrow><mml:mi>&#x003b1;</mml:mi></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="M7"><mml:mi>r</mml:mi><mml:mo>=</mml:mo><mml:mn>.485</mml:mn></mml:math></inline-formula>, <inline-formula><mml:math id="M8"><mml:mi>P</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>.05</mml:mn></mml:math></inline-formula> and <inline-formula><mml:math id="M9"><mml:mi>r</mml:mi><mml:mo>=</mml:mo><mml:mn>.573</mml:mn></mml:math></inline-formula>, <inline-formula><mml:math id="M10"><mml:mi>P</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>.01</mml:mn></mml:math></inline-formula>, resp.). <italic>Conclusion</italic>. Serum ghrelin levels is elevated in acyanotic and cyanotic patients with congenital heart disease. Increased ghrelin levels represents malnutrition and growth retardation in these patients. The relation of ghrelin with cytokines may be explained by the possible effect of chronic congestive heart failure and chronic shunt hypoxemia.</p></abstract></article-meta></front><body><sec sec-type="section" id="sec1"><title>1. INTRODUCTION</title><p>Ghrelin, a 28-amino-acide peptide, is a potent stimulator of growth hormone release that has been implicated in the control of food intake and energy homeostasis in human begins and rodents [<xref ref-type="bibr" rid="B1">1</xref>&#x02013;<xref ref-type="bibr" rid="B5">5</xref>]. Ghrelin is mainly produced in the stomach. Ghrelin is not secreted into the gastrointestinal tract like digestive enzymes but into blood vessels to circulate throughout the body [<xref ref-type="bibr" rid="B6">6</xref>]. Ghrelin causes weight gain by increasing food intake and reducing fat use [<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>]. Ghrelin has effects on nutrient intake and growth hormone (GH) release, subsequently on physical development and growth [<xref ref-type="bibr" rid="B9">9</xref>].</p><p>Tumor necrosis factor <inline-formula><mml:math id="M11"><mml:mrow><mml:mi>&#x003b1;</mml:mi></mml:mrow></mml:math></inline-formula> (TNF-<inline-formula><mml:math id="M12"><mml:mrow><mml:mi>&#x003b1;</mml:mi></mml:mrow></mml:math></inline-formula>) and interleukin-6 (IL-6) are pleiotropic cytokines with numerous immunologic and metabolic actions [<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B11">11</xref>]. IL-6 is generally considered to be an important cytokine in the network of cytokines that regulate immune reactions and acute phase responses [<xref ref-type="bibr" rid="B12">12</xref>].</p><p>The relationship between congenital heart disease (CHD), malnutrition, and growth retardation is well documented [<xref ref-type="bibr" rid="B13">13</xref>]. Infants with congenital heart disease are prone to malnutrition for several reasons including decreased energy intake, increased energy requirements, or both. Different types of cardiac malformations can affect nutrition and growth to varying degrees [<xref ref-type="bibr" rid="B14">14</xref>]. Although nutritional and growth status were investigated in children with cyanotic and acyanotic heart disease, serum ghrelin levels have not been established. The objective of this study is to investigate and compare the functional role of ghrelin on the regulation of energy balance in children with cyanotic and acyanotic congenital heart disease and the association of ghrelin with TNF-<inline-formula><mml:math id="M13"><mml:mrow><mml:mi>&#x003b1;</mml:mi></mml:mrow></mml:math></inline-formula>, IL-6, that were not entirely confirmed in literature by now.</p></sec><sec sec-type="section" id="sec2"><title>2. MATERIAL AND METHODS</title><sec sec-type="subsection" id="subsec2.1"><title>2.1. Study population</title><p>The study was conducted on 47 children with acyanotic CHD, 21 children with cyanotic CHD, and 25 healthy children. All patients' cardiac diagnoses were made on the basis of clinical and laboratory examinations. None of the patients had associated abnormalities or pulmonary hypertension. Body mass index (BMI) was calculated as the ratio of body weight (kg) and squared height (m). The local ethics committee approved the study protocol. Informed consents were obtained from the parents of the subjects.</p></sec><sec sec-type="subsection" id="subsec2.2"><title>2.2. Laboratory investigation and immunoassay</title><p>All blood samples were drawn at 08-09 am and stored &#x02212;20&#x000b0;C until the procedure. Serum ghrelin, TNF-<inline-formula><mml:math id="M14"><mml:mrow><mml:mi>&#x003b1;</mml:mi></mml:mrow></mml:math></inline-formula>, and IL-6 levels were analyzed with ELISA kits (TNF-<inline-formula><mml:math id="M15"><mml:mrow><mml:mi>&#x003b1;</mml:mi></mml:mrow></mml:math></inline-formula>, IL-6 kit was purchased from Bio-Source International Inc. (Camarillo, Calif, USA); Ghrelin kit from Phoenix International, Inc, USA).</p></sec><sec sec-type="subsection" id="subsec2.3"><title>2.3. Statistical analyses</title><p>All data were analyzed by SPSS software, version 10.0 for Windows. Data were presented as mean &#x000b1; standard deviation. The given data were compared between groups using one-way ANOVA, followed by Post-hoc; Bonferroni test. Correlation between the parameters were explored with Spearman's correlation. <inline-formula><mml:math id="M16"><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:math></inline-formula> values less than .05 were considered statistically significant.</p></sec></sec><sec sec-type="section" id="sec3"><title>3. RESULTS</title><p>In 47 acyanotic patients, mean age was <inline-formula><mml:math id="M17"><mml:mn>30.5</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:mn>18.4</mml:mn></mml:math></inline-formula> months, in 21 cyanotic patients was <inline-formula><mml:math id="M18"><mml:mn>28.4</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:mn>15.6</mml:mn></mml:math></inline-formula> months and in 25 control subjects was <inline-formula><mml:math id="M19"><mml:mn>31.1</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:mn>15.1</mml:mn></mml:math></inline-formula> months. Age and anthropometric data of the patients and the control subjects are shown in <xref ref-type="table" rid="tab1">Table 1</xref>. There was no significant difference between groups (the acyanotic patients, the cyanotic patients) in terms of mean age, weight, height, BMI. The specific cardiac lesions of patients are listed in <xref ref-type="table" rid="tab2">Table 2</xref>.</p><p>Serum ghrelin levels were significantly higher than in acyanotic and cyanotic groups compared to in the control group (<inline-formula><mml:math id="M20"><mml:mi>P</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>.0001</mml:mn></mml:math></inline-formula>) (<xref ref-type="table" rid="tab3">Table 3</xref>). Serum ghrelin levels in the acyanotic patients were significantly higher than in the cyanotic patients (<inline-formula><mml:math id="M21"><mml:mi>P</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>.0001</mml:mn></mml:math></inline-formula>). TNF-<inline-formula><mml:math id="M22"><mml:mrow><mml:mi>&#x003b1;</mml:mi></mml:mrow></mml:math></inline-formula> levels were significantly higher than in cyanotic and acyanotic patients with CHD compared to in the control groups (<inline-formula><mml:math id="M23"><mml:mi>P</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>.001</mml:mn></mml:math></inline-formula>, <inline-formula><mml:math id="M24"><mml:mi>P</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>.0001</mml:mn></mml:math></inline-formula>, resp.). Serum TNF-<inline-formula><mml:math id="M25"><mml:mrow><mml:mi>&#x003b1;</mml:mi></mml:mrow></mml:math></inline-formula> values were higher in the acyanotic patients compared to the cyanotic patients with CHD (<inline-formula><mml:math id="M26"><mml:mi>P</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>.001</mml:mn></mml:math></inline-formula>). Serum IL-6 levels were higher than in cyanotic and acyanotic patients with CHD compared to in the control groups (<inline-formula><mml:math id="M27"><mml:mi>P</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>.0001</mml:mn></mml:math></inline-formula>, <inline-formula><mml:math id="M28"><mml:mi>P</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>.001</mml:mn></mml:math></inline-formula>, resp.).</p><p>In both acyanotic and cyanotic groups, serum ghrelin levels were negatively correlated with BMI (<inline-formula><mml:math id="M29"><mml:mi>r</mml:mi><mml:mo>=</mml:mo><mml:mo>&#x02212;</mml:mo><mml:mn>.549</mml:mn></mml:math></inline-formula>, <inline-formula><mml:math id="M30"><mml:mi>P</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>.05</mml:mn></mml:math></inline-formula> and <inline-formula><mml:math id="M31"><mml:mi>r</mml:mi><mml:mo>=</mml:mo><mml:mo>&#x02212;</mml:mo><mml:mn>.688</mml:mn></mml:math></inline-formula>, <inline-formula><mml:math id="M32"><mml:mi>P</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>.01</mml:mn></mml:math></inline-formula>, resp.) (Figures <xref ref-type="fig" rid="fig1">1(a)</xref> and <xref ref-type="fig" rid="fig1">1(b)</xref>). IL-6 and TNF-<inline-formula><mml:math id="M33"><mml:mrow><mml:mi>&#x003b1;</mml:mi></mml:mrow></mml:math></inline-formula> levels were not related to BMI in the acyanotic and cyanotic patients with CHD. Ghrelin levels were also correlated with TNF-<inline-formula><mml:math id="M34"><mml:mrow><mml:mi>&#x003b1;</mml:mi></mml:mrow></mml:math></inline-formula> in the acyanotic and cyanotic groups (<inline-formula><mml:math id="M35"><mml:mi>r</mml:mi><mml:mo>=</mml:mo><mml:mn>.485</mml:mn></mml:math></inline-formula>, <inline-formula><mml:math id="M36"><mml:mi>P</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>.05</mml:mn></mml:math></inline-formula> and <inline-formula><mml:math id="M37"><mml:mi>r</mml:mi><mml:mo>=</mml:mo><mml:mn>.573</mml:mn></mml:math></inline-formula>, <inline-formula><mml:math id="M38"><mml:mi>P</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>.01</mml:mn></mml:math></inline-formula>, resp.) (Figures <xref ref-type="fig" rid="fig2">2(a)</xref> and <xref ref-type="fig" rid="fig2">2(b)</xref>). Ghrelin levels were not related to IL-6 in the acyanotic and cyanotic patients with CHD (<inline-formula><mml:math id="M39"><mml:mi>r</mml:mi><mml:mo>=</mml:mo><mml:mo>&#x02212;</mml:mo><mml:mn>.263</mml:mn></mml:math></inline-formula>, <inline-formula><mml:math id="M40"><mml:mi>P</mml:mi><mml:mo>&#x0003e;</mml:mo><mml:mn>.05</mml:mn></mml:math></inline-formula> and <inline-formula><mml:math id="M41"><mml:mi>r</mml:mi><mml:mo>=</mml:mo><mml:mn>.398</mml:mn></mml:math></inline-formula>, <inline-formula><mml:math id="M42"><mml:mi>P</mml:mi><mml:mo>&#x0003e;</mml:mo><mml:mn>.05</mml:mn></mml:math></inline-formula>, resp.).</p></sec><sec sec-type="section" id="sec4"><title>4. DISCUSSION</title><p>The cause of growth retardation in CHD is multifactorial. Inadequate caloric intake, malabsorption, and increased energy requirements caused by increased metabolism may all contribute. However, inadequate caloric intake appears to be the most important cause of growth failure in CHD [<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B16">16</xref>]. Patients with acyanotic heart disease had a greater growth deficit in weight, and those with cyanotic heart disease had a greater growth deficit in stature as demonstrated by both decreased height and weight. Although growth impairment is most pronounced in infants with cyanotic CHD, growth failure does not correlate well with the degree of hypoxia. In this study, the cyanotic patients had a more pronounced retardation in both height and weight than in the acyanotic patients [<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B17">17</xref>].</p><p>Ghrelin is accepted as a good marker of the nutritional state, mainly in situations of malnutrition, like anorexia nervosa, owing its fast recovery after weight gain [<xref ref-type="bibr" rid="B18">18</xref>]. The inverse correlation between ghrelin levels and BMI is well defined [<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B19">19</xref>]. We observed the mentioned correlation, both in children with cyanotic heart disease and in children with acyanotic heart disease.</p><p>Although the cyanotic patients had a more pronounced retardation in both height and weight than in the acyanotic patients, we found that serum ghrelin levels significantly elevated in the acyanotic patients than in the cyanotic patients (<inline-formula><mml:math id="M43"><mml:mi>P</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>.0001</mml:mn></mml:math></inline-formula>). Growth failure in cyanotic children has not been shown to be proportional to the severity of cyanosis, suggesting that multiple factors are involved in the pathogenesis of their growth disturbance [<xref ref-type="bibr" rid="B20">20</xref>]. Alteration of endocrine mediators of growth has been implicated as a possible mechanism of growth failure in cyanotic patients. Cyanotic newborn lambs have decreased levels of serum insulin-like growth factor I without a corresponding decrease in growth hormone or hepatic growth factor receptors [<xref ref-type="bibr" rid="B21">21</xref>]. Weintraub et al. [<xref ref-type="bibr" rid="B22">22</xref>] reported that while insulin-like growth factor I levels were linearly related to height and weight in patients with cyanotic lesions, no such correlation was found in their cyanotic patients. These studies suggest that chronic tissue hypoxia may have independent role in growth failure.</p><p>We found that serum TNF-<inline-formula><mml:math id="M44"><mml:mrow><mml:mi>&#x003b1;</mml:mi></mml:mrow></mml:math></inline-formula> significantly increased in the cyanotic patients and in the acyanotic patients. Similarly, serum IL-6 was increased in both groups but the change was more distinctive in the cyanotic patients. TNF-<inline-formula><mml:math id="M45"><mml:mrow><mml:mi>&#x003b1;</mml:mi></mml:mrow></mml:math></inline-formula> and IL-6 appear to be important cachectic process mediators, although this association is not completely established [<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B24">24</xref>]. Cardiac cachexia describes wasting primarily due to loss of lean body mass. Cachexia results in decreased muscle strength and function and compromised immune function [<xref ref-type="bibr" rid="B25">25</xref>, <xref ref-type="bibr" rid="B26">26</xref>]. This syndrome is likely to occur in children who have chronic congestive heart failure, chronic shunt hypoxemia [<xref ref-type="bibr" rid="B27">27</xref>]. In addition to inadequate calorie and protein intake, there is evidence that this syndrome may be caused by circulating tumor necrosis factor, which stimulates catabolism [<xref ref-type="bibr" rid="B28">28</xref>].</p><p>In the present study, ghrelin correlated to positively with TNF-<inline-formula><mml:math id="M46"><mml:mrow><mml:mi>&#x003b1;</mml:mi></mml:mrow></mml:math></inline-formula>, in acyanotic patients and cyanotic patients with CHD. The relation of ghrelin with TNF-<inline-formula><mml:math id="M47"><mml:mrow><mml:mi>&#x003b1;</mml:mi></mml:mrow></mml:math></inline-formula> raises the possibility of the direct effect of TNF-<inline-formula><mml:math id="M48"><mml:mrow><mml:mi>&#x003b1;</mml:mi></mml:mrow></mml:math></inline-formula> upon ghrelin or the impact of heart failure severity upon both ghrelin and TNF-<inline-formula><mml:math id="M49"><mml:mrow><mml:mi>&#x003b1;</mml:mi></mml:mrow></mml:math></inline-formula>. Nagaya et al. [<xref ref-type="bibr" rid="B29">29</xref>] have shown that plasma ghrelin level is increased in cachectic patients with congestive heart failure as a compensatory mechanism in response to anabolic-catabolic imbalance.</p><p>In conclusion, serum ghrelin level is elevated in cyanotic and acyanotic patients with CHD. Increased ghrelin levels represents malnutrition and growth retardation in these patients. Additionally, the relation of ghrelin with cytokines may be explained by the possible effect of chronic congestive heart failure and chronic shunt hypoxemia.</p></sec></body><back><ref-list><ref id="B1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arvat</surname><given-names>E</given-names></name><name><surname>Di Vito</surname><given-names>L</given-names></name><name><surname>Broglio</surname><given-names>F</given-names></name><etal/></person-group><article-title>Preliminary evidence that Ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans</article-title><source><italic>Journal of Endocrinological Investigation</italic></source><year>2000</year><volume>23</volume><issue>8</issue><fpage>493</fpage><lpage>495</lpage><pub-id pub-id-type="pmid">11021763</pub-id></citation></ref><ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Peino</surname><given-names>R</given-names></name><name><surname>Baldelli</surname><given-names>R</given-names></name><name><surname>Rodriguez-Garcia</surname><given-names>J</given-names></name><etal/></person-group><article-title>Ghrelin-induced growth hormone secretion in humans</article-title><source><italic>European Journal of Endocrinology</italic></source><year>2000</year><volume>143</volume><issue>6</issue><fpage>11</fpage><lpage>14</lpage></citation></ref><ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wren</surname><given-names>AM</given-names></name><name><surname>Small</surname><given-names>CJ</given-names></name><name><surname>Abbott</surname><given-names>CR</given-names></name><etal/></person-group><article-title>Ghrelin causes hyperphagia and obesity in rats</article-title><source><italic>Diabetes</italic></source><year>2001</year><volume>50</volume><issue>11</issue><fpage>2540</fpage><lpage>2547</lpage><pub-id pub-id-type="pmid">11679432</pub-id></citation></ref><ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsch&#x000f6;p</surname><given-names>M</given-names></name><name><surname>Weyer</surname><given-names>C</given-names></name><name><surname>Tataranni</surname><given-names>PA</given-names></name><name><surname>Devanarayan</surname><given-names>V</given-names></name><name><surname>Ravussin</surname><given-names>E</given-names></name><name><surname>Heiman</surname><given-names>ML</given-names></name></person-group><article-title>Circulating ghrelin levels are decreased in human obesity</article-title><source><italic>Diabetes</italic></source><year>2001</year><volume>50</volume><issue>4</issue><fpage>707</fpage><lpage>709</lpage><pub-id pub-id-type="pmid">11289032</pub-id></citation></ref><ref id="B5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsch&#x000f6;p</surname><given-names>M</given-names></name><name><surname>Smiley</surname><given-names>DL</given-names></name><name><surname>Heiman</surname><given-names>ML</given-names></name></person-group><article-title>Ghrelin induces adiposity in rodents</article-title><source><italic>Nature</italic></source><year>2000</year><volume>407</volume><issue>6806</issue><fpage>908</fpage><lpage>913</lpage><pub-id pub-id-type="pmid">11057670</pub-id></citation></ref><ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kojima</surname><given-names>M</given-names></name><name><surname>Hosoda</surname><given-names>H</given-names></name><name><surname>Kangawa</surname><given-names>K</given-names></name></person-group><article-title>Ghrelin, a novel growth-hormone-releasing and appetite-stimulating peptide from stomach</article-title><source><italic>Best Practice and Research in Clinical Endocrinology and Metabolism</italic></source><year>2004</year><volume>18</volume><issue>4</issue><fpage>517</fpage><lpage>530</lpage></citation></ref><ref id="B7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nakazato</surname><given-names>M</given-names></name><name><surname>Murakami</surname><given-names>N</given-names></name><name><surname>Date</surname><given-names>Y</given-names></name><etal/></person-group><article-title>A role for ghrelin in the central regulation of feeding</article-title><source><italic>Nature</italic></source><year>2001</year><volume>409</volume><issue>6817</issue><fpage>194</fpage><lpage>198</lpage><pub-id pub-id-type="pmid">11196643</pub-id></citation></ref><ref id="B8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>HS</given-names></name><name><surname>Lee</surname><given-names>K-U</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name><name><surname>Park</surname><given-names>CY</given-names></name></person-group><article-title>Relationships between fasting plasma ghrelin levels and metabolic parameters in children and adolescents</article-title><source><italic>Metabolism Clinical and Experimental</italic></source><year>2005</year><volume>54</volume><issue>7</issue><fpage>925</fpage><lpage>929</lpage><pub-id pub-id-type="pmid">15988702</pub-id></citation></ref><ref id="B9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Whatmore</surname><given-names>AJ</given-names></name><name><surname>Hall</surname><given-names>CM</given-names></name><name><surname>Jones</surname><given-names>J</given-names></name><name><surname>Westwood</surname><given-names>M</given-names></name><name><surname>Clayton</surname><given-names>PE</given-names></name></person-group><article-title>Ghrelin concentrations in healthy children and adolescents</article-title><source><italic>Clinical Endocrinology</italic></source><year>2003</year><volume>59</volume><issue>5</issue><fpage>649</fpage><lpage>654</lpage><pub-id pub-id-type="pmid">14616891</pub-id></citation></ref><ref id="B10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beutler</surname><given-names>B</given-names></name><name><surname>Cerami</surname><given-names>A</given-names></name></person-group><article-title>Cachectin (tumor necrosis factor): a macrophage hormone governing cellular metabolism and inflammatory response</article-title><source><italic>Endocrine Reviews</italic></source><year>1988</year><volume>9</volume><issue>1</issue><fpage>57</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">3286235</pub-id></citation></ref><ref id="B11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tracey</surname><given-names>KJ</given-names></name><name><surname>Cerami</surname><given-names>A</given-names></name></person-group><article-title>Tumor necrosis factor: a pleiotropic cytokine and therapeutic target</article-title><source><italic>Annual Review of Medicine</italic></source><year>1994</year><volume>45</volume><fpage>491</fpage><lpage>503</lpage></citation></ref><ref id="B12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Le</surname><given-names>J</given-names></name><name><surname>Vilcek</surname><given-names>J</given-names></name></person-group><article-title>Interleukin 6: a multifunctional cytokine regulating immune reactions and the acute phase protein response</article-title><source><italic>Laboratory Investigation</italic></source><year>1989</year><volume>61</volume><issue>6</issue><fpage>588</fpage><lpage>602</lpage><pub-id pub-id-type="pmid">2481148</pub-id></citation></ref><ref id="B13"><label>13</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Abad-Sinden</surname><given-names>A</given-names></name><name><surname>Sutphen</surname><given-names>JL</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Allan</surname><given-names>DH</given-names></name><name><surname>Gutgesell</surname><given-names>HP</given-names></name><name><surname>Clark</surname><given-names>EB</given-names></name><name><surname>Driscoll</surname><given-names>DJ</given-names></name></person-group><article-title>Growth and nutrition</article-title><source><italic>Moss and Adams' Heart Disease in Infants, Children, and Adolescents</italic></source><year>2001</year><publisher-loc>Philadelphia, Pa, USA</publisher-loc><publisher-name>Lippincott Williams &#x00026; Wilkins</publisher-name><fpage>325</fpage><lpage>332</lpage></citation></ref><ref id="B14"><label>14</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Gilger</surname><given-names>M</given-names></name><name><surname>Jensen</surname><given-names>C</given-names></name><name><surname>Kessler</surname><given-names>B</given-names></name><name><surname>Nanjundiah</surname><given-names>P</given-names></name><name><surname>Klish</surname><given-names>WJ</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Garson</surname><given-names>A</given-names></name><name><surname>Bricker</surname><given-names>JT</given-names></name><name><surname>McNamara</surname><given-names>PG</given-names></name></person-group><article-title>Nutrition, growth, and gastrointestinal system: basic knowledge for pediatric cardiologist</article-title><source><italic>The Science and Practice of Pediatric Cardiology</italic></source><year>1990</year><publisher-loc>Philadelphia, Pa, USA</publisher-loc><publisher-name>Lea &#x00026; Febiger</publisher-name><fpage>2354</fpage><lpage>2370</lpage></citation></ref><ref id="B15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Unger</surname><given-names>R</given-names></name><name><surname>DeKleermaeker</surname><given-names>M</given-names></name><name><surname>Gidding</surname><given-names>SS</given-names></name><name><surname>Christoffel</surname><given-names>KK</given-names></name></person-group><article-title>Calories count. Improved weight gain with dietary intervention in congenital heart disease</article-title><source><italic>American Journal of Diseases of Children</italic></source><year>1992</year><volume>146</volume><issue>9</issue><fpage>1078</fpage><lpage>1084</lpage><pub-id pub-id-type="pmid">1514555</pub-id></citation></ref><ref id="B16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Varan</surname><given-names>B</given-names></name><name><surname>Tokel</surname><given-names>K</given-names></name><name><surname>Yilmaz</surname><given-names>G</given-names></name></person-group><article-title>Malnutrition and growth failure in cyanotic and acyanotic congenital heart disease with and without pulmonary hypertension</article-title><source><italic>Archives of Disease in Childhood</italic></source><year>1999</year><volume>81</volume><issue>1</issue><fpage>49</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">10373135</pub-id></citation></ref><ref id="B17"><label>17</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Gingell</surname><given-names>RL</given-names></name><name><surname>Hornung</surname><given-names>MG</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Lebenthal</surname><given-names>E</given-names></name></person-group><article-title>Growth problems associated with congenital heart disease in infancy</article-title><source><italic>Textbook of Gastroenterology and Nutrition in Infancy</italic></source><year>1989</year><publisher-loc>New York, NY, USA</publisher-loc><publisher-name>Raven Press</publisher-name><fpage>639</fpage><lpage>649</lpage></citation></ref><ref id="B18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Soriano-Guill&#x000e9;n</surname><given-names>L</given-names></name><name><surname>Barrios</surname><given-names>V</given-names></name><name><surname>Argente</surname><given-names>J</given-names></name></person-group><article-title>Physiopathological features and diagnostic utility of ghrelin protein in pediatrics</article-title><source><italic>Anales de Pediatria</italic></source><year>2004</year><volume>61</volume><issue>1</issue><fpage>5</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">15228927</pub-id></citation></ref><ref id="B19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haqq</surname><given-names>AM</given-names></name><name><surname>Farooqi</surname><given-names>IS</given-names></name><name><surname>O'Rahilly</surname><given-names>S</given-names></name><etal/></person-group><article-title>Serum ghrelin levels are inversely correlated with body mass index, age, and insulin concentrations in normal children and are markedly increased in Prader-Willi syndrome</article-title><source><italic>The Journal of Clinical Endocrinology and Metabolism</italic></source><year>2003</year><volume>88</volume><issue>1</issue><fpage>174</fpage><lpage>178</lpage><pub-id pub-id-type="pmid">12519848</pub-id></citation></ref><ref id="B20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baum</surname><given-names>D</given-names></name><name><surname>Beck</surname><given-names>RQ</given-names></name><name><surname>Haskell</surname><given-names>WL</given-names></name></person-group><article-title>Growth and tissue abnormalities in young people with cyanotic congenital heart disease receiving systemic-pulmonary artery shunts</article-title><source><italic>The American Journal of Cardiology</italic></source><year>1983</year><volume>52</volume><issue>3</issue><fpage>349</fpage><lpage>352</lpage><pub-id pub-id-type="pmid">6869286</pub-id></citation></ref><ref id="B21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bernstein</surname><given-names>D</given-names></name><name><surname>Jasper</surname><given-names>JR</given-names></name><name><surname>Rosenfeld</surname><given-names>RG</given-names></name><name><surname>Hintz</surname><given-names>RL</given-names></name></person-group><article-title>Decreased serum insulin-like growth factor-I associated with growth failure in newborn lambs with experimental cyanotic heart disease</article-title><source><italic>Journal of Clinical Investigation</italic></source><year>1992</year><volume>89</volume><issue>4</issue><fpage>1128</fpage><lpage>1132</lpage><pub-id pub-id-type="pmid">1372914</pub-id></citation></ref><ref id="B22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weintraub</surname><given-names>RG</given-names></name><name><surname>Menahem</surname><given-names>S</given-names></name><name><surname>Werther</surname><given-names>G</given-names></name></person-group><article-title>Serum insulin-like growth factor I levels in patients congenital heart disease</article-title><source><italic>Australian Paediatric Journal,vol 25</italic></source><year>1989</year><volume>25</volume><fpage>324</fpage><lpage>325</lpage></citation></ref><ref id="B23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Inui</surname><given-names>A</given-names></name></person-group><article-title>Cancer anorexia-cachexia syndrome: are neuropeptides the key?</article-title><source><italic>Cancer Research</italic></source><year>1999</year><volume>59</volume><issue>18</issue><fpage>4493</fpage><lpage>4501</lpage><pub-id pub-id-type="pmid">10493494</pub-id></citation></ref><ref id="B24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kotler</surname><given-names>DP</given-names></name></person-group><article-title>Cachexia</article-title><source><italic>Annals of Internal Medicine</italic></source><year>2000</year><volume>133</volume><issue>8</issue><fpage>622</fpage><lpage>634</lpage><pub-id pub-id-type="pmid">11033592</pub-id></citation></ref><ref id="B25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Freeman</surname><given-names>LM</given-names></name><name><surname>Roubenoff</surname><given-names>R</given-names></name></person-group><article-title>The nutrition implications of cardiac cachexia</article-title><source><italic>Nutrition Reviews</italic></source><year>1994</year><volume>52</volume><issue>10</issue><fpage>340</fpage><lpage>347</lpage><pub-id pub-id-type="pmid">7816351</pub-id></citation></ref><ref id="B26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morrison</surname><given-names>WL</given-names></name><name><surname>Edwards</surname><given-names>RHT</given-names></name></person-group><article-title>Cardiac cachexia</article-title><source><italic>British Medical Journal</italic></source><year>1991</year><volume>302</volume><issue>6772</issue><fpage>301</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">2001502</pub-id></citation></ref><ref id="B27"><label>27</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Rosenthal</surname><given-names>A</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Suskind</surname><given-names>RM</given-names></name><name><surname>Levinter-Suskind</surname><given-names>L</given-names></name></person-group><article-title>Nutritional conciderations in the prognosis treatment of children with congenital heart disease</article-title><source><italic>Textbook of Pediatric Nutrition</italic></source><year>1993</year><publisher-loc>New York, NY, USA</publisher-loc><publisher-name>Raven Press</publisher-name><fpage>383</fpage><lpage>391</lpage></citation></ref><ref id="B28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McMurray</surname><given-names>J</given-names></name><name><surname>Abdullah</surname><given-names>I</given-names></name><name><surname>Dargie</surname><given-names>HJ</given-names></name><name><surname>Shapiro</surname><given-names>D</given-names></name></person-group><article-title>Increased concentrations of tumour necrosis factor in &#x02018;cachectic&#x02019; patients with severe chronic heart failure</article-title><source><italic>British Heart Journal</italic></source><year>1991</year><volume>66</volume><issue>5</issue><fpage>356</fpage><lpage>358</lpage><pub-id pub-id-type="pmid">1747295</pub-id></citation></ref><ref id="B29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nagaya</surname><given-names>N</given-names></name><name><surname>Uematsu</surname><given-names>M</given-names></name><name><surname>Kojima</surname><given-names>M</given-names></name><etal/></person-group><article-title>Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors</article-title><source><italic>Circulation</italic></source><year>2001</year><volume>104</volume><issue>17</issue><fpage>2034</fpage><lpage>2038</lpage><pub-id pub-id-type="pmid">11673342</pub-id></citation></ref></ref-list></back><floats-wrap><fig position="float" id="fig1"><label>Figure 1</label><caption><p>(a) Correlation of ghrelin with BMI in acyanotic patients with CHD (<inline-formula><mml:math id="M50" overflow="scroll"><mml:mi>r</mml:mi><mml:mo>=</mml:mo><mml:mo>&#x02212;</mml:mo><mml:mn>.549</mml:mn></mml:math></inline-formula>, <inline-formula><mml:math id="M51" overflow="scroll"><mml:mi>P</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>.05</mml:mn></mml:math></inline-formula>). (b) Correlation of ghrelin with BMI in cyanotic patients with CHD (<inline-formula><mml:math id="M52" overflow="scroll"><mml:mi>r</mml:mi><mml:mo>=</mml:mo><mml:mo>&#x02212;</mml:mo><mml:mn>.688</mml:mn></mml:math></inline-formula>, <inline-formula><mml:math id="M53" overflow="scroll"><mml:mi>P</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>.01</mml:mn></mml:math></inline-formula>).</p></caption><graphic xlink:href="MI2007-32403.001" alt-version="no" position="float" xlink:type="simple"/></fig><fig position="float" id="fig2"><label>Figure 2</label><caption><p>(a) Correlation of ghrelin with TNF-<inline-formula><mml:math id="M54" overflow="scroll"><mml:mrow><mml:mi>&#x003b1;</mml:mi></mml:mrow></mml:math></inline-formula> in acyanotic patients with CHD (<inline-formula><mml:math id="M55" overflow="scroll"><mml:mi>r</mml:mi><mml:mo>=</mml:mo><mml:mn>.485</mml:mn></mml:math></inline-formula>, <inline-formula><mml:math id="M56" overflow="scroll"><mml:mi>P</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>.05</mml:mn></mml:math></inline-formula>). (b) Correlation of ghrelin with TNF-<inline-formula><mml:math id="M57" overflow="scroll"><mml:mrow><mml:mi>&#x003b1;</mml:mi></mml:mrow></mml:math></inline-formula> in cyanotic patients with CHD (<inline-formula><mml:math id="M58" overflow="scroll"><mml:mi>r</mml:mi><mml:mo>=</mml:mo><mml:mn>.573</mml:mn></mml:math></inline-formula>, <inline-formula><mml:math id="M59" overflow="scroll"><mml:mi>P</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>.01</mml:mn></mml:math></inline-formula>).</p></caption><graphic xlink:href="MI2007-32403.002" alt-version="no" position="float" xlink:type="simple"/></fig><table-wrap position="float" id="tab1"><label>Table 1</label><caption><p>Age and anthropometric data of the patients and the control subjects.</p></caption><table><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Cyanotic patients </th><th align="center" rowspan="1" colspan="1">Acyanotic patients</th><th align="center" rowspan="1" colspan="1">Control</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M60" overflow="scroll"><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>21</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:math></inline-formula></th><th align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M61" overflow="scroll"><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>47</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:math></inline-formula></th><th align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M62" overflow="scroll"><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>25</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:math></inline-formula></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (month)</td><td align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M63" overflow="scroll"><mml:mn>30.5</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:mn>18.4</mml:mn></mml:math></inline-formula></td><td align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M64" overflow="scroll"><mml:mn>28.4</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:mn>15.6</mml:mn></mml:math></inline-formula></td><td align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M65" overflow="scroll"><mml:mn>31.1</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:mn>15.1</mml:mn></mml:math></inline-formula></td></tr><tr><td align="left" rowspan="1" colspan="1">Female/Male ratio</td><td align="center" rowspan="1" colspan="1">10/11</td><td align="center" rowspan="1" colspan="1">30/17</td><td align="center" rowspan="1" colspan="1">15/10</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight (kg)</td><td align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M66" overflow="scroll"><mml:mn>9.7</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:mn>7.4</mml:mn></mml:math></inline-formula></td><td align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M67" overflow="scroll"><mml:mn>10.9</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:mn>6.2</mml:mn></mml:math></inline-formula></td><td align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M68" overflow="scroll"><mml:mn>21.2</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:mn>9.9</mml:mn></mml:math></inline-formula></td></tr><tr><td align="left" rowspan="1" colspan="1">Height (cm)</td><td align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M69" overflow="scroll"><mml:mn>76.8</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:mn>26.8</mml:mn></mml:math></inline-formula></td><td align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M70" overflow="scroll"><mml:mn>83.6</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:mn>21.9</mml:mn></mml:math></inline-formula></td><td align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M71" overflow="scroll"><mml:mn>98.4</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:mn>22.9</mml:mn></mml:math></inline-formula></td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M72" overflow="scroll"><mml:mn>14.9</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:mn>2</mml:mn></mml:math></inline-formula></td><td align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M73" overflow="scroll"><mml:mn>14.6</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:mn>2.1</mml:mn></mml:math></inline-formula></td><td align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M74" overflow="scroll"><mml:mn>21.5</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:mn>5.5</mml:mn></mml:math></inline-formula></td></tr></tbody></table></table-wrap><table-wrap position="float" id="tab2"><label>Table 2</label><caption><p>Diagnosis of the patients.</p></caption><table><thead><tr><th rowspan="1" colspan="1">Diagnosis</th><th align="center" rowspan="1" colspan="1">No.</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"><italic><bold>Cyanotic patients</bold></italic></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"> Tetralogy of Fallot</td><td align="center" rowspan="1" colspan="1">15</td></tr><tr><td align="left" rowspan="1" colspan="1"> Tricuspid atresia</td><td align="center" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1"> Transposition of great arteries</td><td align="center" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1"> Truncus arteriosus</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic><bold>Acyanotic patients</bold></italic></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"> Ventricular septal defect</td><td align="center" rowspan="1" colspan="1">35</td></tr><tr><td align="left" rowspan="1" colspan="1"> Atrial septal defect</td><td align="center" rowspan="1" colspan="1">11</td></tr><tr><td align="left" rowspan="1" colspan="1"> Patent ductus arteriosus</td><td align="center" rowspan="1" colspan="1">1</td></tr></tbody></table></table-wrap><table-wrap position="float" id="tab3"><label>Table 3</label><caption><p>Ghrelin, TNF-<inline-formula><mml:math id="M75" overflow="scroll"><mml:mrow><mml:mi>&#x003b1;</mml:mi></mml:mrow></mml:math></inline-formula>, and IL-6 levels of patients with CHD and control groups.</p></caption><table><thead><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Cyanotic patients</th><th align="center" rowspan="1" colspan="1">Acyanotic patients</th><th align="center" rowspan="1" colspan="1">Control</th></tr><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M76" overflow="scroll"><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>21</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:math></inline-formula></th><th align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M77" overflow="scroll"><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>47</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:math></inline-formula></th><th align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M78" overflow="scroll"><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>25</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:math></inline-formula></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Ghrelin (ng/ml)</td><td align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M79" overflow="scroll"><mml:mn>19.2</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:msup><mml:mn>5.9</mml:mn><mml:mrow><mml:mtext>b</mml:mtext><mml:mo>,</mml:mo><mml:mtext>c</mml:mtext></mml:mrow></mml:msup></mml:math></inline-formula></td><td align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M80" overflow="scroll"><mml:mn>41.9</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:msup><mml:mn>11.6</mml:mn><mml:mrow><mml:mtext>a</mml:mtext></mml:mrow></mml:msup></mml:math></inline-formula></td><td align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M81" overflow="scroll"><mml:mn>8.6</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:mn>1.7</mml:mn></mml:math></inline-formula></td></tr><tr><td align="left" rowspan="1" colspan="1">TNF-<inline-formula><mml:math id="M82" overflow="scroll"><mml:mrow><mml:mi>&#x003b1;</mml:mi></mml:mrow></mml:math></inline-formula> (pg/ml)</td><td align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M83" overflow="scroll"><mml:mn>11</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:msup><mml:mn>4.1</mml:mn><mml:mrow><mml:mtext>e</mml:mtext><mml:mo>,</mml:mo><mml:mtext>f</mml:mtext></mml:mrow></mml:msup></mml:math></inline-formula></td><td align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M84" overflow="scroll"><mml:mn>18.8</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:msup><mml:mn>5.4</mml:mn><mml:mrow><mml:mtext>a</mml:mtext></mml:mrow></mml:msup></mml:math></inline-formula></td><td align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M85" overflow="scroll"><mml:mn>7.5</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:mn>3.4</mml:mn></mml:math></inline-formula></td></tr><tr><td align="left" rowspan="1" colspan="1">IL-6 (pg/ml)</td><td align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M86" overflow="scroll"><mml:mn>16.2</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:msup><mml:mn>6.9</mml:mn><mml:mrow><mml:mtext>b</mml:mtext></mml:mrow></mml:msup></mml:math></inline-formula></td><td align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M87" overflow="scroll"><mml:mn>13.6</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:msup><mml:mn>5.8</mml:mn><mml:mrow><mml:mtext>d</mml:mtext></mml:mrow></mml:msup></mml:math></inline-formula></td><td align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M88" overflow="scroll"><mml:mn>3.2</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:mn>1.4</mml:mn></mml:math></inline-formula></td></tr></tbody></table><table-wrap-foot><fn><p><inline-formula><mml:math id="M91" overflow="scroll"><mml:msup><mml:mi/><mml:mtext>a</mml:mtext></mml:msup><mml:mi>P</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>.0001</mml:mn></mml:math></inline-formula> control: acyanotic group</p></fn><fn><p><inline-formula><mml:math id="M92" overflow="scroll"><mml:msup><mml:mi/><mml:mtext>b</mml:mtext></mml:msup><mml:mi>P</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>.0001</mml:mn></mml:math></inline-formula> control: cyanotic group</p></fn><fn><p><inline-formula><mml:math id="M93" overflow="scroll"><mml:msup><mml:mi/><mml:mtext>c</mml:mtext></mml:msup><mml:mi>P</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>.0001</mml:mn></mml:math></inline-formula> cyanotic: acyanotic group</p></fn><fn><p><inline-formula><mml:math id="M95" overflow="scroll"><mml:msup><mml:mi/><mml:mtext>d</mml:mtext></mml:msup><mml:mi>P</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>.001</mml:mn></mml:math></inline-formula> control: acyanotic group</p></fn><fn><p><inline-formula><mml:math id="M97" overflow="scroll"><mml:msup><mml:mi/><mml:mtext>e</mml:mtext></mml:msup><mml:mi>P</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>.001</mml:mn></mml:math></inline-formula> cyanotic: acyanotic group</p></fn><fn><p><inline-formula><mml:math id="M99" overflow="scroll"><mml:msup><mml:mi/><mml:mtext>f</mml:mtext></mml:msup><mml:mi>P</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>.01</mml:mn></mml:math></inline-formula> control: cyanotic group</p></fn></table-wrap-foot></table-wrap></floats-wrap></article> 